Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy

Yuh-Jyh Lin,T. Yeh,W. Hsieh,Yun‐Chan Chi,Hong C. Lin,Chyi-Her Lin
DOI: https://doi.org/10.1002/(SICI)1099-0496(199901)27:1<21::AID-PPUL5>3.0.CO;2-Y
IF: 4.0899
1999-01-01
Pediatric Pulmonology
Abstract:Recent studies suggest that early dexamethasone therapy may lessen the pulmonary inflammation in preterm infants with respiratory distress syndrome (RDS). To investigate whether early (<12 hr) postnatal dexamethasone therapy would reduce the incidence of chronic lung disease (CLD), a randomized, double‐blind, controlled trial was conducted in 40 infants (birth weights from 500 to 1,999 gm) who had severe RDS and required mechanical ventilation within 6 hr of birth. All infants received one dose of Survanta® before they were randomly assigned to control (saline placebo) or dexamethasone‐treated groups (0.5 mg/kg/d for 1 week, then tapered over 3 weeks). Sequential analysis was performed with the end point of assessment being the presence or absence of CLD on postnatal Day 28.
What problem does this paper attempt to address?